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We examined the effects ofchronic exposure to radionuclides, primarily uranium and mixed-fis-
sionproducts, on cancermortality in aretrospective cohortstudyofworkersenrolled in the radia-
tion-monitoring program of a nuclear research and development facility. Between 1950 and
1994, 2,297 workerswere monitored for intenal radiationexposures, and 441 workers died, 134
(30.4%) ofthem from cancer as the underlying cause. We calculated internal lung-dose estimates
based on urinalysis and whole-body and lung counts reported for individual workers. We exam-
ined cancer mortality ofworkers exposed at diffirent cumulative lung-dose levels using complete
risk-set analysis for cohort data, adjusting forage, pay type, time since first radiation monitored,
and external radiation. In addition, we examined the potential for confounding due to chemical
exposures and smoking, explored whether external radiation exposure modifies the effects of
internal exposure, and estimated effects afterexcduding exposures likely to have been unrelated to
disease onset. Dose-response relations were observed for death from hemato- and lymphopoietic
cancers and from upper aerodigestive tract cancers, adjusting for age, time since first monitored,
pay type, and external (gamma) radiation dose. No association as found for other cancers,
including cancers ofthe lung. Despite the small number-ofexposed deaths from specific cancer
types and possible bias due to measurement error and confounding, the positive findings and
strong dose-response gradients observed suggest carcinogenic effects ofinternal radiation to the
upper aerodigestive tract and the blood and lymph system in this occupational cohort. However,
causal inferences require replication ofour results in other populations or confirmation with an
extended follow-up ofthis cohort. Key words cancer mortality, hematopoietic cancers, internal
(alpha) radiation, lymphopoietic.cancers, occupational cohort study, upperaerodigestive tract can-
cers. EnvironHealtbPerpct108:743-751 (2000). (Online 28June20001
kttp://ehpnetl.nie/s.ni/.gov/docs/2000/108p743-75li*s/abstraa.iltml
Compared to a wealth of information about
effects of low-dose external radiation expo-
sures (gamma and X rays), considerably fewer
data are available for quantifying human
health risks associated with chronic internal
exposure to radionuclides. In animal experi-
ments, high internal doses from alpha- and
beta/gamma-emitting radionuclides have
resulted in immunosuppressive and carcino-
genic effects in organs where these radionu-
clides concentrate (1). The carcinogenic
potential ofsuch radionuclides has been con-
firmed in a few human populations exposed
to high doses, including uranium miners and
millers, radium dial painters, and patients
treated with Thorotrast and 224Ra (2,3). The
sites of cancer have coincided with distribu-
tion patterns for the radionuclides within the
body, with increases in the incidence oflung,
liver, and head-sinus carcinomas, as well as
leukemias and bone sarcomas.
Studies published to date examining
health effects in workers in the nuclear
industry who were exposed internally to
radionuclides have yielded inconsistent find-
ings at dose levels less than 1 Sv (100 rem)
(Table 1). The lack of consistency may be
partly a function of differences in the types
of alpha radiation-emitting particles to
which workers have been exposed at differ-
ent nuclear facilities; for example, some
workers were primarily exposed to 239Pu and
238Pu, others to uranium dusts, a mixture of
tritium, plutonium, and other radionuclides,
and others to 222Rn or 210po (Table 1). After
ingestion or inhalation, radioactive particles,
depending on their size, solubility, and
chemical structure, differ in their distribu-
tion through the body, their organ residence
time, and the transfer, dissolution, and
absorption of the radioactivity associated
with the particles (3), and hence might be
expected to vary in their effects across organ
systems. Moreover, there has been consider-
able variation from study to study in the
methods used to estimate internal dose lev-
els. Some studies simply used monitoring
status and/or duration as a crude proxy mea-
sure of internal exposure, whereas others
relied on environmental monitoring of air-
borne dust concentrations to approximate
personal exposures. Several studies used
more extensive dose-modeling approaches
based on variable combinations ofurinalysis,
fecal analysis, and in vivo organ or whole-
body count data, sometimes in association
with environmental measures, to calculate
whole-body burden (a measure that applies
an equal dose to all organs) or organ-specific
doses such as to the lung, kidney, or spleen
(Table 1). Because of large differences in
exposure assessment and the lack ofpower in
smaller cohorts with the most in-depth expo-
sure characterization, comparisons ofinternal
dose levels and of results across studies are
problematic and the generalizability of find-
ings may be limited. However, although this
heterogeneity across studies may prohibit us
from calculating a common effect estimate or
validly comparing results across studies, each
study contributes information about the
potential carcinogenicity of specific radionu-
clides prevalent in the work environment ofa
nuclear facility.
In our study we calculated lung doses
using several kinds of individual-level moni-
toring data provided by the facility to exam-
ine the cancer mortality risk associated
primarily with exposures to uranium and
mixed-fission products. Most ofthe employ-
ees included in the analyses were also moni-
tored for external (gamma) radiation.
Materials and Methods
Study Design and Subject Selection
We carried out a retrospective cohort mortal-
ity study ofworkers employed since 1950 at
Rocketdyne/Atomics International (RAI), of
whom 4,607 were enrolled in the company's
health physics radiation monitoring program
between 1 January 1950 and 31 December
1993. The analyses were restricted to those
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2,297 workers involved in nuclear fuel
assembly and disassembly operations who
were monitored for internal radionuclide
exposure. We chose to exclude radiation
workers who were not monitored for internal
exposures for two reasons: to minimize expo-
sure misclassification, since some unmoni-
tored workers probably were exposed to
radionuclides, especially before 1963; and to
minimize possible selection bias resulting
from differences in unmeasured risk factors
between monitored and unmonitored work-
ers, a phenomenon demonstrated in the
Rocky Flats cohort by Wilkinson and
Morgenstern (23).
It was necessary to exclude 39 otherwise
eligible workers for whom the records lacked
enough information to determine vital sta-
tus. We did not restrict the cohort on the
basis ofemployment duration, race, or gen-
der. All but 44 of the workers included in
the internal radiation assessments had also
been monitored for external radiation expo-
sure. Follow-up for each subject began at the
start ofinternal monitoring or on 1 January
1950, whichever date was later. Follow-up
ended on the date ofdeath ofa cohort mem-
ber or on 31 December 1994, whichever
date came earlier.
Ascertainment ofDeaths
Vital status determinations identified 441
subjects who died between 1959 and 1994.
We received death certificates of vested
cohort members from the company. If two
independent company data sources identi-
fied an employee as active, and thus alive, at
the end offollow-up, we counted him or her
as living. About 10% ofthe cohort members
were identified as living.
Employees not identified as alive or dead
by company records were checked against
three different record systems: the Social
Security Administration (SSA) beneficiary-
records files (period covered, 1935-1994),
the vital statistics files for the State of
California (period covered, 1960-1994),
and the U.S. National Death Index (NDI)
(period covered, 1979-1994). Matches were
verified from a review of information on
death certificates. We were able to obtain all
but 12 death certificates for deceased sub-
jects. Among these 12 deaths, 7 (58%)
workers were unexposed, 4 (33%) belonged
to the 1-< 5 mSv group, and 1 (8%) to the
5-30 mSv group. Because this exposure dis-
tribution is similar to the one observed for
all workers (Table 2), we concluded that we
did not differentially lose exposed or unex-
posed workers, and thus did not expect this
lack ofinformation to bias our results.
The underlying and contributing causes
of death recorded on the certificates were
coded using the International Classification
ofDiseases, Ninth Revision (ICD-9) (24,25)
by a licensed nosologist. The accuracy ofthe
coding was verified by members ofthe study
team. For some analyses the ICD-9 codes
were translated into Eighth Revision ofthe
International Classification ofDiseases (ICD-
8) codes (Table 3). All results presented in
this paper are based on cancers as the under-
lying cause ofdeath.
Radiation Measurements
Throughout the study period, RAI conduct-
ed periodic bioassays of urine or feces, as
well as in vivo whole-body counts and lung
counts, to estimate internal doses for work-
ers assigned to areas potentially contaminat-
ed by radioactive materials. These doses
resulted from inhalation and, to a lesser
Table 2. Characteristics of 2,297 cohort members monitored for internal radiation, by sex.
Number of employees
Average follow-up time (years)
Average age at entry into cohort(years)
Number of person-years
Number of deaths
Total mortality rate (per 105/year)
Total cancer mortality rate (per 105/year)
Pay type
Salaried managerial/professional
Salaried technical/administrative
Hourly/union
Unknown
Internal radiation dose (mSv)
0
0-<5
5-<30
>30
Male
2,218
25.5
34.5
56,610
433
764.9
234.9
682
189
1,272
75
1,279
672
250
17
Female
79
23.1
33.7
1,827
8
437.9
54.7
Total (%)
2,297
25.4
34.5
58,837
441
749.5
227.7
25
33
18
3
707
214
1,290
78
54
19
6
0
1,333 (58.0)
691 (30.1)
256 (11.2)
17(0.7)
Table 3. Observed (OBS) and expected (EXP) numbers of deaths among male subjects and estimated
SMR, by cause of death: comparison with the U.S. white male population.
Cause of death
All causes of death (ICD-8 001-998)
All cancers (ICD-8 140-229)
Cancers
Buccal cavity and pharynx (ICD-8 140-149)
Digestive organs and peritoneum (ICD-8 150-159)
Esophagus (ICD-8 150)
Stomach (ICD-8 151)
Large intestines (ICD-8 153)
Pancreas (ICD-8 157)
Respiratory system (ICD-8 160-163)
Larynx (ICD-8 161)
Lung, primary and secondary (ICD-8 162)
Skin (ICD-8 172,173)
Prostate (ICD-8 185)
Bladder (lCD-8 188)
Kidney (ICD-8 189)
Brain and other central nervous system (ICD-8 191,192)
Leukemia and aleukemia (ICD-8 204-207)
Lymphopoietic cancer(ICD-8 200-208)
Other causes
All diseases of circulatory system (ICD-8 390-458)
Arteriosclerotic heart disease, including CHD (ICD-8 410-414)
All vascular lesions of CNS (ICD-8 430-438)
All respiratory diseases (ICD-8 460-519)
Emphysema (ICD-8 492)
All diseases of digestive system (ICD-8 520-577)
Cirrhosis of liver (ICD-8 571)
All diseases of genito-urinary system (ICD-8 580-629)
All external causes of death (ICD-8 800-998)
Suicide (ICD-8 950-959)
Total residuala
Cancer residualb
No.
OBS
433
133
3
36
5
6
15
8
50
4
46
5
7
3
5
6
8
12
183
118
20
30
7
12
9
5
35
9
12
5
No.
EXP
598.32
152.72
4.05
36.67
3.84
5.07
13.54
7.49
59.46
2.01
56.95
3.48
9.59
3.39
3.97
4.60
5.47
14.45
270.24
192.61
26.98
40.26
6.27
28.98
16.69
6.44
56.54
14.88
1.30
11.75
SMR 95% Cl
0.72 0.66-0.80
0.87 0.73-1.03
0.74
0.98
1.30
1.18
1.11
1.07
0.84
1.99
0.81
1.44
0.73
0.89
1.26
1.31
1.46
0.83
0.68
0.61
0.74
0.75
1.12
0.41
0.54
0.78
0.62
0.60
9.22
0.43
0.15-2.16
0.69-1.36
0.42-3.04
0.43-2.57
0.62-1.83
0.46-2.11
0.62-1.11
0.54-5.11
0.59-1.08
0.46-3.36
0.29-1.50
0.18-2.59
0.41-2.94
0.48-2.84
0.63-2.88
0.43-1.45
0.58-0.78
0.51-0.73
0.45-1.15
0.50-1.06
0.45-2.30
0.21-0.72
0.25-1.02
0.25-1.81
0.43-0.86
0.28-1.15
Abbreviations: SMR, standardized mortality ratio; Cl, confidence interval.
"lncluding undetermined causes of death and missing causes of death due to missing death certificates. bCancers of
unspecified site.
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degree, ingestion and skin absorption of
radionuclides. Most ofthe available internal
dose records were for the period 1963-1983.
Before 1963, few measures ofinternal expo-
sures were taken, and by 1983, all major
operations involving radionuclides had been
discontinued. Company policy during the
early years was to monitor only those indi-
viduals with a significant possibility of
receiving annual lung-dose equivalents in
excess of150 mSv.
We calculated an estimated internal
cumulative dose to the lung for each
employee. The primary radionuclides
included in the dose estimates were a) urani-
um, with a range of degrees of enrichment
for 235U; b) mixed-fission products (unspeci-
fied as to radionuclide); c) 90Sr; a) 137Cs;
and e) small amounts ofplutonium. In addi-
tion, measurements of gross beta and gross
alpha radiation in samples were available for
some individuals. Methods for converting
bioassay results to annual dose (in units of
millisieverts) were based on the biokinetic
models of International Commission on
Radiological Protection publications (26,27)
and on the mathematical techniques
described in a report by Crawford-Brown
and co-workers (28,29). This approach
yielded the following conversion factors for
the primaryradionuclides ofinterest:
* For uranium urinalyses, each 15 dpm
excreted per day translates to an average
value of 5 niSv exposure to the lung per
year. This conversion factor represents a
mean lung removal half-time of 120 days
and a urine excretion fraction of0.8.
* For in vivo uranium lung counts, the con-
version factor is obtained directly from the
RAI estimate ofthe percent maximum per-
missible lung burden. In each case, the
time-averaged percent maximum permissi-
ble lung burden (%MPLB ) for an individ-
ual is multiplied by 1.5 mSv. The
conversion factor for the dose to the bone
marrow is approximately0.2 mSv/%MPLB.
* For mixed-fission products, the conversion
depends on the availability ofinformation
on the radionudide involved. In cases where
the radionuclide was specified in the records
(e.g., 90Sr or 137Cs), committed effective
dose equivalents had already been calculated
bythe facility health physics staff. These cal-
culations were checked and, ifconfirmed,
usedasthedose foranindividual. Where the
radionuclide was not specified, a representa-
tive conversion factor based on an assump-
tion of90Sr intakes and a class Y retention
half-time in thelungwas used. The resulting
conversion factor is 5 mSv/year to the lung
per250dpmexcretedperday.
* For plutonium, the conversion factor used
was 10 mSv/year exposure to the lung per
disintegrations per minute per day. This
factor is appropriate for a class Y plutoni-
um compound.
For urinalysis measurements ofuranium,
plutonium, and mixed-fission products, we
used radiometric or fluorometric techniques.
The more reliable radiometric method was
the primary basis ofdose estimation for ura-
nium intakes in this study. When records
listed "mixed-fission products," it was possi-
ble only in a few cases to determine the
radionuclide present in the sample. In addi-
tion, therewere limited in vivolungcounting
results for 235U. For every worker, we exam-
ined records for each of the radionuclides
separately and sorted them by calendar time
within each year. A time-weighted average
measurement for an individual was then
obtained for each year by weighting each
reading in that year by the fraction of the
year until the next reading in the temporal
sequence. For example, ifXI were a reading
obtained on 1 January of a year and ifX2
were a reading obtained on July 1 of that
same year, then the average for the year
would be 0.5Xj + 0.5X2, since each reading
would represent the exposure measure for
approximately 50% ofthat year. The excep-
tion was at the end ofthe monitoring period
(indicated by the end ofmonitoring records
for an individual), in which case the radionu-
clide was assumed to be removed with a half-
life depending on the particular radionudide,
and the resulting integral of activity versus
time was calculated. We obtained a time-
weighted average lung burden for each
worker. More than 95% of the reported or
calculated doses from internal exposures were
from uranium and mixed-fission products.
At RAI, the health physics team identified
workers potentially exposed to significant
internal radiation doses from airborne conta-
minants for inclusion in a routine quarterly
monitoring program. Some workers were
monitored only in the event of accidents
involving radioactive material spills. Thus,
there might be no measurements available for
an individual during a certain period, even
though exposure may have occurred. Most
records did not distinguish between routine
and accident-driven monitoring, and we
assumed that the record represented a routine
measurement. Consequently, the assumption
oftime weighting used in this study overesti-
mates doses for instances in which the mea-
surement was due to an accident, butwas not
designated assuch.
Fortunately, it was possible to separate
routine and accident-related measurements
for individuals with large annual doses (> 10
mSv in a year). For other measurements that
were due to an accident, however, we overes-
timated the true average annual dose by
counting the measurement as an average dose,
instead ofaone-time peakdose. On theother
hand, a potential for underestimation of the
true average annual dose existed due to the
minimum detection limits (MDLs) of the
assay methods in use (the MDL was 2 mSv
for uranium and plutonium and 0.5 mSv for
mixed-fission products).
We used RAI records of external radia-
tion monitoring, including whole-body dose
measurements for gamma rays and X rays, to
calculate cumulative dose from external
exposure (30). For those 44 workers never
monitored for external radiation exposure,
we assumed an external dose of0 mSv.
Treatment ofPotential Confounders
We used personnel and medical records to
explore such potential confounders as occu-
pational/socioeconomic status, race, work-
place exposure to carcinogenic chemicals,
and smoking history. Based on personnel
records, workers were assigned to one of
three pay-type categories (hourly, salaried
technical/administrative, or managerial/pro-
fessional); this variable was used as a proxy
for occupational/socioeconomic status.
Employees who changed titles or pay type
were categorized according to the titles and
pay types held longest at RAI. The 78 sub-
jects lacking job titles and pay type were
assigned to the hourly category. Because RAI
did not systematically collect data on the
race of its employees before 1972, we were
unable to control for the influence of this
factor in our analyses. According to the
information on death certificates, however,
96% ofall deceasedworkers werewhite.
Job titles, employment periods, and,
when available, job locations were used to
create proxy measures for chemical exposures
during the study period. We determined
that hydrazine, asbestos, beryllium, and
many solvents had been used extensively at
Rocketdyne/AI. We categorized workers as
highly, moderately, potentially, or not likely
to be exposed to asbestos and hydrazine.
Information about tobacco smoking was
systematically recorded for two subgroups of
subjects in routinely administered medical
questionnaires from different periods.
Questionnaires from 1961 to 1969 indicated
only whether the worker was a smoker
(yes/no); after 1980, thelevel ofsmoking and
dates ofstarting and quitting were specified.
Because information on smoking was not
available for most of the study cohort, we
examined the association between smoking
status and cumulative radiation dose in those
workers for whom information on smoking
was available (658 subjects) to assess potential
confounding in the largercohort.
Statistical Methods
We used two different analytic approaches:
external comparisons of our monitored
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workers with the general U.S. white male
population; and internal comparisons
among monitored workers according to
measured dose levels of radiation exposure
(dose-response analyses). In external com-
parisons, the Monson program (31) was used
to estimate standardized mortality ratios
(SMRs; = observed/expected deaths) for the
monitored study population. We estimated
expected numbers ofdeaths from the mortal-
ity rates of the U.S. white male population,
stratified byage (5-yearcategories) and calen-
dar year (5-year intervals). Estimation of
95% confidence limits for the SMRs was
based on a formula derived by Byar and rec-
ommended byBreslowand Day(32).
Because our study population yielded 10
or fewer deaths for many types ofcancer, it
was not possible to perform informative
dose-response analyses; thus, it was neces-
sary to combine deaths from selected can-
cers. The choice ofwhich cancers and cancer
groups to evaluate was made apriori on the
basis of the distribution within the body of
the radionuclides of major concern. These
radionuclides emit densely ionizing alpha
radiation that usually reaches and damages
only the tissues in its immediate vicinity-
within micrometers of the particle (1).
Exceptions are the air-filled spaces in the
lung, which allow alpha particles to reach
greater distances, such that almost any tissue
constituent ofthe lung may receive a consid-
erable dose of radiation, and radionuclides
that dissolve from particles into systemic cir-
culation from which they deposit in other
tissues. Cells located at bifurcations, where
removal is significantly slower than in the
tubular airways, will experience significantly
higher doses than those lining the tubular
airways. In addition, for alpha emitters such
as those considered here, microdosimetric
considerations show that most cells will have
a dose ofzero, with a small fraction ofcells
having doses on the order oftens ofrads due
to the passage ofone or a few alpha particles
through the nucleus. Because risk coeffi-
cients generally are developed using mean
tissue doses, however, we chose to use mean
dose in the present study rather than the
more detailed microscopic dosedistribution.
Relatively insoluble radioactive particles
that reach the alveoli are gradually translo-
cated to tracheobronchial and other thoracic
lymph nodes, which may accumulate con-
centrations of inhaled material several hun-
dred times greater than in the regions ofthe
lung (1). Larger particles (2 10 pm) rarely
reach the lower respiratory tract or, ifthey
do, are cleared rapidly and completely. Such
particles can deliver intense doses ofconcen-
trated alpha radiation to regions ofthe naso-
and oropharyngeal systems and the upper
gastrointestinal tract.
Thus, any effects of internally deposited
radionuclides are most likely to be evident in
those tissues receiving the highest dose. In
general, these will be the tissues ofthe portal
organs (lungs for inhalation and gastro-
intestinal tract for ingestion) for the highly
insoluble compounds, or the bone for the
more soluble compounds (for translocation
ofuranium and strontium). Because solubili-
ty is unknown for this population, itwas not
possible to estimate doses to tissues other
than the lung tissue, and even for the lung
we obtained only a relative measure ofdose,
as the absolute value ofthe dose depends on
solubility. Accordingly, we conducted
dose-response analyses for a) lung cancer
(ICD-9 162); b) upper aerodigestive tract
cancers encompassing the naso-oropharyn-
geal regions, esophagus, and stomach (ICD-
9 140-151); c) hemato- and lymphopoietic
cancers (ICD-9 200-208, excluding chronic
lymphatic leukemias); a) urinary-tract can-
cers (ICD-9 188-189); and e) prostate can-
cer (ICD-9 185). Other organs to which
some radionuclides are translocated and
stored are the liver (Thorotrast), bones (plu-
tonium), and the thyroid (iodine). We did
not, however, observe any bone, thyroid, or
primary liver cancers among workers moni-
tored for internal radiation.
To estimate effects in the dose-response
analyses, we used the risk-set approach for
the analysis ofcohort study data, which was
recommended by Breslow and Day (32),
using the full cohort information. In this
approach, conditional logistic regression is
used to compare individuals who have died
ofcancer (outcome events) with all individu-
als still at risk of dying from cancer (sur-
vivors). We constructed risk sets of deaths
and survivors matched on calendar time for
use in the analysis by matching to each can-
cer death all cohort members who were still
alive at the time ofthe index subject's death.
This approach allowed us to treat cumulative
dose and all other time-varying variables,
such as time since first monitoring, as time
dependent, (i.e., values for these factors were
determined for all risk-set members at the
time ofeach indexdeath).
We modeled cumulative internal radia-
tion dose both as a set ofbinary variables and
as a continuous variable (in 10-mSv incre-
ments). Based on the dose distribution in our
cohort, we categorized dose equivalents into 4
levels: 0 mSv, > 0-5 mSv, > 5-< 30 mSv, and
> 30 mSv. To allow for a period of induc-
tion/latency between radiation exposure and
cancer death and to reduce possible selection
bias (33), we lagged cumulative doses by 0, 2,
and 10 years. Lagging entailed limiting the
level ofcumulative dose for each individual in
a risk set to the dose level achieved 0, 2, and
10 years before the index death occurred. As
recommended, we adjusted in all models for
time since first monitored to avoid the possi-
ble selection bias inherent in the analyses of
cumulative exposures (34).
We used results ofthe conditional logistic
regression analyses to estimate rate ratios (RR)
and 95% confidence intervals (CI) for inter-
nal radiation and other covariates in the
model. To test for a monotonic trend in the
association between cumulative dose and can-
cer mortality, the mean ofthe four dose cate-
gories were used as exposure scores. We
explored a variety of potential confounders,
but retained in the final models only those
covariates that changed the estimated RR for
radiation exposure by> 10% foranyoutcome
(35). Accordingly, pay status, time since first
monitored, and age at risk (continuous) but
not exposure to chemicals were included in all
models presented in this paper. Because
Checkoway et al. (6) reported a positive asso-
ciation between internal and external radia-
tion dose in Oak Ridge workers, all analyses
ofinternal radiation effects were also adjusted
for the effect ofexternal radiation dose (treat-
edas continuous in 10-mSvincrements).
Results
The Rocketdyne/AI cohort monitored for
internal radiation exposure was characterized
by a long follow-up period (average 25.4
years), ahigh percentage ofsalaried employees
(40.1%), and few women (Table 2). Only
0.7% of these workers received estimated
internal radiation doses to the lung > 30 mSv,
andslighdymore than halfoftheworkershad
recorded doses of0 mSv.
During the study period, 19.2% of the
cohort members died (441 total deaths). We
observed 133 deaths from canceras the under-
lying cause among males and one such cancer
death among females, yielding a total cancer
mortlityrateof235 per 105/year (Table 1).
Comparing the mortality experience of
male RAI workers monitored for internal
radiation with the white male U.S. popula-
tion resulted in SMRs of 0.72 (95% CI,
0.66-0.80) for all causes, 0.87 (95% CI,
0.73-1.03) for all cancers, and 0.68 (95%
CI, 0.58-0.78) for all circulatory system dis-
eases (Table 3). These results indicate that
members of the RAI cohort are healthier
than the general population [i.e., a strong
healthy worker (selection) effect exists], an
effect wewould expect to observe in a cohort
with a large proportion of higher socioeco-
nomic status employees and extensive health
insurance coverage (see also "Discussion").
For specific cancer sites, we did not observe
SMRs for which the 95% CIs excluded the
null value of1.
In dose-response analyses, monotonic
associations were observed between cumu-
lative internal dose and mortality from
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hemato- and lymphopoietic cancers and
from cancers ofthe upper aerodigestive tract
(Tables 4 and 5). The rate ratios for hemato-
and lymphopoietic cancers, comparing a
cumulative dose . 30 mSv with 0 mSv, was
44.6 (95% CI, 5.64-353), and the corre-
sponding rate ratio for upper-aerodigestive
tract cancers was 57.2 (95% CI, 8.17-401).
Total cancer mortality was also elevated
somewhat for cumulative doses > 30 mSv
(RR = 2.56; 95% CI, 0.93-7.09). We found
no effects of internal radiation on mortality
from lung cancer, urinary tract cancers, or
prostate cancer (Tables 4 and 5). Lagging
doses by 2 and 10 years did not change the
results of the analyses (Table 5), nor did
adding to the cancers specified as underlying
causes ofdeath all cancers listed as contribut-
ing causes (results not shown).
For the 2,253 workers monitored for
both external and internal radiation, we esti-
mated the combined effects on total cancer
mortality of both types of radiation, cross-
classified into nine dose categories. Although
there were no cancer deaths in the highest
combined dose category (> 200 mSv exter-
nal and > 30 mSv internal radiation), the
cancer mortality RRswere elevated apprecia-
bly (RR > 5) for monitored workers in the
next highest combined dose categories
(Table 6). However, the 95% confidence
intervals are quite wide for these estimates,
indicating low precision of these estimates
based on small numbers.
We did not find an association between
smoking and cumulative internal radiation
dose during the 1960s (Table 7). On the
other hand, exposed workers who were still
employed in the 1980s were more likely than
unexposedworkers to have quit smoking, and
the fraction of unexposed workers who con-
tinued smoking remained disproportionately
high relative to both their exposed co-workers
and California males in general (36).
Discussion
We observed a strong healthy worker (selec-
tion) effect in our cohort: compared to the
U.S. population, monitored RAI nuclear
workers experienced lower rates of death
from all causes, from all cancers, and partic-
ularly from all circulatory system diseases.
This phenomenon is characteristic of occu-
pational cohorts in general, but is especially
strong in the nuclear industries for which
mean all-cause SMRs have been reported to
be even lower (0.79) than the corresponding
mean SMRs (0.83) reported for a large num-
ber of other industries (37). The all-cause
SMR in our cohort is low (0.72) mainly
because RAI employees exhibit a large deficit
in cardiovascular disease mortality (SMR =
0.62) which may be due to differences in
lifestyle factors (diet, smoking, physical
activity) when comparing these Californian
workers to the rest of the United States or
may be related to the extensive health insur-
ance coverage these nuclear workers enjoyed
throughout their employment. Greater
health insurance coverage of workers may
also be responsible for reducing fatality rates
of many common cancers such as those of
the colon, prostate, and bladder; for these
organs, fatality depends on early detection
and medical treatment ofthe cancer (38).
Exposure levels in the cohort studiedwere
relatively low; the mean lung dose from inter-
nal radionuclide exposure for 2,297 moni-
tored workers was estimated to be 2.1 mSv, a
dose much lower, for example, than the aver-
age lung dose of82.1 mSv reported for 3,491
Table 4. Adjusted rate ratio (RR) estimates (and 95% confidence intervals) forthe effect of cumulative internal radiation dose and otherfactors on cancer mortali-
ty, by cancertype, assuming zero lag for exposure: results of conditional logistic regression analyses.
Predictors All cancers
Age atriskb 1.10
(1.08-1.12)
Time since first 0.99
monitoredb.c (0.97-1.01)
Pay type
Salaried managerial/ 0.75
professional vs. other (0.51-1.10)
External radiation dose 1.02
(10 mSv)cd (0.98-1.06)
Internal radiation dose (mSv)c
0 1.00
(n =79)e
> 0-< 5 0.86 (0.58-1.27)
(n=36)
2 5-<30 0.87 (0.45-1.67)
(n= 15)
.30 2.56(0.93-7.09)
(n=4)
pfortrendf 0.087
Hemato- and lympho-
poietic cancers
(ICD-9 200-208)a
1.10
(1.03-1.18)
0.99
(0.89-1.09)
1.05
(0.26-4.27)
1.06
(1.00-1.13)
1.00
In=2)
2.31 (0.37-14.2)
(n=3)
6.10(0.89-41.7)
(n=3)
44.6(5.64-353)
(n=2)
0.0001
Lung cancers
(ICD-9 162)
1.10
(1.07-1.13)
0.97
(0.93-1.02)
0.49
(0.21-0.97)
1.06
(1.01-1.11)
1.00
In=30)
0.58(0.28-1.21)
)n=9)
0.45(0.12-1.67)
(n=5)
0.00
(n=0)
0.20
Upper aerodigestive
tract cancers
(ICD-9 140-151)
1.09
(1.04-1.15)
0.94
(0.85-1.03)
0.64
(0.17-2.35)
0.92
(0.76-1.12)
1.00
In=3)
4.75(1.12-20.2)
In=6)
10.56(1.91-58.4)
(n=3)
57.2(8.17-401)
(n=2)
0.0001
Bladder and
kidney cancers
(ICD-9 188,189)
1.18
(1.09-1.27)
0.95
(0.84-1.07)
0.79
(0.16-4.06)
1.05
(0.91-1.21)
1.00
(n=5)
1.07 (0.23-5.02)
In=3)
0.00
(n=0)
0.00
(n=0)
0.43
Prostate cancers
(ICD-9 185)
1.20
(1.10-1.31)
0.98
(0.92-1.04)
1.23
(0.22-6.95)
0.19
(0.03-1.32)
1.00
In=5)
1.59(0.28-9.06)
In=2)
0.00
(n=0)
0.00
(n=0)
0.65
&Excluding chronic lymphatic leukemias. bMeasured in one year increments. cTreated as time-dependent. dAssumes dose due to radionuclides equal to zero for employees not moni-
tored for external radiation. Measured in 10-mSv increments. 'Number of cancer deaths shown in parentheses. frhe test for trend was performed by entering an interval variable with
the category means as the score values into the logistic regression model.
Table 5. Adjusted rate ratio (RR) estimate (and 95% confidence interval) and two-tailed p-value for the effect of cumulative internal radiation dose in 10-mSV
increments, by cancertype and lag for exposure: results of conditional logistic regression analyses.
Internal All cancers
radiation dose (n= 134)
(per 10mSv) RR p
0-year lag 1.03(0.88-1.20) 0.70
2-year lag 1.03 (0.89-1.21) 0.66
10-year lag 1.04(0.88-1.22) 0.68
&Excluding chronic lymphatic leukemias.
Hematopoietic and
lymphopoietic cancersa
(ICD-9 200-208)
n= 10
RR p
1.23(0.97-1.55) 0.08
1.23 (0.97-1.55) 0.08
1.24(0.98-1.55) 0.07
Lung cancers
(ICD-9 162)
n = 44
RR p
0.75(0.32-1.76) 0.50
0.76(0.33-1.76) 0.52
0.74(0.29-1.92) 0.54
Upperaerodigestive
tractcancers
(ICD-9 140-151)
n= 14
RR p
1.25(1.05-1.48) 0.01
1.25(1.05-1.49) 0.01
1.23(1.01-1.50) 0.04
Bladder and
kidney cancers
(ICD-9 188, 189)
n=8
RR p
0.13(0.00-18.5) 0.42
0.13(0.00-18.8) 0.43
0.19 (0.00-20.8) 0.49
Prostate cancers
(ICD-9 185)
n=7
RR p
0.08(0.00-375) 0.56
0.08(0.00-374) 0.56
0.09 (0.00-371) 0.57
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workers monitored for uranium exposure at
the Oak Ridge Y-12 facility (6). Moreover,
because the quality of our internal radiation
data did not allow us to calculate specific
organ doses other than to the lung, all inter-
nal exposure risk estimates were calculated on
the basis ofexpected doses to the lung. Thus,
we relied on lung doses to approximate dose
levels to a range of organs involved in
radionuclide passage through the body (see
Methods), some ofwhich mayhave been sub-
jected to very different levels of exposure,
depending on the radioactive decay process
and the retention function ofthe radionudide
for different organs. Although the computed
lung doses can serve as crude indicators ofthe
magnitude ofdoses delivered to other organs,
our dose estimates should be interpreted in
relative rather than in absolute terms. In gen-
eral, dose comparisons with other studies may
not be appropriate even for those also relying
on lung doses because we lacked information
on solubility, on which accurate estimates of
lungdose depend.
Despite these limitations, we detected
increases in mortality from hemato- and lym-
phopoietic cancers with increasing internal
radiation dose among RAI employees, a find-
ing also reported by two previous studies of
nuclear workers exposed to plutonium
(4,5,18). Wilkinson et al. (4) reported that
Rocky Flats employees with positive plutoni-
um body burdens experienced elevated
mortality from blood and lymphatic system
cancers. These results were more pronounced
and showed a dose-response gradient when
the follow-up of the Rocky Flats cohort was
extended (5). Omar et al. (18) observed an
increase in the incidence ofthese cancers with
increasing cumulative plutonium plus exter-
nal radiation doses among Sellafield workers.
Elevated rates ofhemato- and lymphopoietic
cancers have also been observed in groups of
medical patients treated with high doses of
Thorotrast (3). Archer et al. (39) reported an
SMR of 4 for these cancers among uranium
miners and millers (based on four cases), and
Waxweiler et al. (4Q) found a small increase
for lymphatic cancers among uranium millers
(also based on small numbers).
The dose-response relationship that we
observed between internal radiation exposure
and death from cancers of the upper aerodi-
gestive tract has not previously been described
in occupational cohorts exposed to low doses.
At high levels of exposure, radium dial
painters have suffered an excess ofhead-sinus
cancers (3). Furthermore, the effect estimates
based on the continuous dose (Table 5) did
not change when we considered only the 11
esophageal and gastric cancers out of the
group of 14 upper aerodigestive tract cancers.
Wilkinson (41) reported a strong ecologic
association between uranium deposits and
gastric cancer mortality among counties in
New Mexico. These results should be inter-
preted with caution, however, because ofpos-
sible ecologic bias (42) and confounding due
to the effects ofother environmental carcino-
gens such as arsenic andcadmium.
Other studies of nuclear workers have
not reported increases in cancers ofthe upper
aerodigestive tract at (lung) doses apparently
higher than those in our cohort, yet it is not
clearwhether other researchers everexamined
effects on these organs in a dose-response
analysis. Our external comparisons did not
alert us to an excess mortality for cancers of
these organs compared to the general U.S.
population, possibly because RAI workers
drank less alcohol (the observed number of
liver cirrhosis deaths was about half that
expected; Table 3), while dose-response
analyses showed strongeffects with increasing
radionuclide exposure. Thus, researchers
using external comparisons to guide their
choice oforgan sites for dose-response analy-
ses may have been misled. Our positive find-
ings maybe due, in part, to thelongfollow-up
period in our study and the properties ofthe
radioactive particles to which workers at RAI
were exposed. Moreover, the true dose deliv-
ered to the upper aerodigestive tract may be
higher than indicated by our exposure mea-
sures, which were calculated as doses to the
lung and derived mainly from urinalysis and
lung-count data. Although most internal
exposures are likely to involve inhalation,
some radionuclide particles, depending on
size, will not reach the lower respiratory tract
or will be cleared by the ciliary system and
swallowed. Because such particles have little
or no residence time in the lungs, they are
unlikely to be detected in a lung count.
Because they are excreted through feces, they
would also be missed by urinalysis; however,
fecal analyses were rarely performed in our
cohort. Nevertheless, these particles can
deliver intense doses of concentrated alpha
radiation to regions ofthe naso- and oropha-
ryngeal and upper gastrointestinal system (1).
Thus, our dose categories based on lung-dose
estimates should be interpreted in a qualita-
tive rather than quantitative fashion for the
gastro-intestinal tract and other organs. It is
reasonable, however, to assume that workers
with higher lung doses were at greater risk for
exposure to non-respirable radioactive parti-
cles, although the ratio ofrespirable to non-
respirable particles mayhavevaried.
The observed excess rate of total cancer
mortality in workers in the highest dose cate-
gory (> 30 mSv) (Table 4) is due entirely to
Table 6. Adjusted rate ratio (RR) estimates (and 95% CIs) for the combined effects of cumulative internal and external radiation dose on total cancer mortality
among all 2,253 subjects monitored for both internal and external radiation, by dose level assuming a zero year lag for both exposures: results from a conditional
logistic regression analyses.,
Internal dose
<5mSv 25to<30mSv 230mSv
External dose No. of cancer deaths RR No. of cancer deaths RR No. of cancer deaths RR
< 20 mSv 92 1.00b 5 0.86 2 2.05
(0.35-2.12) (0.50-8.38)
20-< 200 mSv 21 1.18 4 0.84 2 5.99
(0.73-1.90) (0.31-2.30) (1.47-24.45)
>200 mSv 1 1.36 3 5.33 0
(0.19-9.79) (1.66-17.10)
"Adjusted for age at risk, pay type (salaried managerial/professional versus other), and time since firstinternally monitored. bReference category.
Table 7. Smoking prevalence for internally monitored cohort members who were included in a medical survey containing questions aboutsmoking at two different
periods, by cumulative internal radiation dose level.
1961-1969 1980-1992
No.of No.of No.of No.of No.of
Dose level (mSv) smokers (%) nonsmokers (%) Total (%) smokers (%) ex-smokers (%) nonsmokers (%) Total (%)
0 170(64.2) 95(35.8) 265(100) 40(42.1) 31 (32.6) 24(25.3) 95(100)
>0 152(64.4) 84(35.6) 236(100) 18(29.0) 28(45.2) 16(25.8) 62(100)
Total 322 (64.3) 179(35.7) 501(100) 58(36.9) 59(37.6) 40(25.5) 157 (100)
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deaths from cancers ofthe hemato- and lym-
phopoietic system and upper aerodigestive
tract. We did not observe an effect ofinternal
radiation on cancers of the urinary tract or
prostate among RAI workers. British studies
found increased incidence rates of prostate
and renal cancers in nuclear workers who
were either exposed primarily to tritium or to
a variety ofdifferent radionuclides (14-16).
Our negative results for urinary tract and
prostate cancers might be attributable to the
absence of tritium exposures in our cohort,
the lower power ofour study, lower radionu-
clide doses delivered to the urinary system
(perhaps with a greater degree of partition-
ing to the gastrointestinal tract), or the use
of mortality rather than incidence data.
Furthermore, the absence of bone, liver, or
thyroid cancers may be due to the fact that
RAI workers were primarily exposed to ura-
nium compounds and not other radionu-
clides favorably deposited in the latter two
organs and/or the small number ofsuch can-
cers expected in our cohort.
We also did not detect a positive associa-
tion between internal radiation dose and lung
cancer mortality in ourcohort. British studies
demonstrated a trend ofincreasing mortality
from lung cancers with increasing external
radiation doses only among those workers
who were also monitored for internal expo-
sure to radionuclides, and an overall increase
in respiratory tract cancers among plutonium
workers could not be explained by external
radiation doses (14-16). Similarly, at Oak
Ridge Y-12, Checkoway et al. (6) found the
strongest gradient for the effect ofcumulative
gamma radiation dose (external) on lung can-
cer mortality in a subgroup of workers
exposed to > 50 mSv ofinternal alpha radia-
tion, primarily from uranium. Dupree et al.
(7) were unable to confirm these results when
extending the Oak Ridge follow-up by 3
years. However, the later analysis differed
from the original in one important aspect:
nonmonitored workers were included in the
unexposed group. Wiggs et al. (10) reported
a slightly elevated lung cancer mortality
among plutonium-exposed workers at the
Los Alamos National Laboratories. Fernald
uranium processingworkers exposed to alpha
radiation at levels > 200 mSv also experi-
enced an increased risk of dying from lung
cancers (9). Several Russian studies ofpluto-
nium workers employed at the Mayak
nuclear enterprise recently also reported an
increased risk oflung cancers among workers
exposed to high levels ofplutonium (19-22).
The lack of a positive association
between lung cancer mortality and radionu-
clide dose in our cohort may be due to RAI
workers having actually received relatively
low doses to the lung tissue, very few work-
ers having been exposed to plutonium, or
incomplete control for confounding byother
risk factors. The most likely potential con-
founders are smoking and exposure to chem-
ical carcinogens such as asbestos, hydrazine,
and beryllium. We did not have the infor-
mation necessary to adjust for beryllium
exposures, and our measures ofasbestos and
hydrazine exposure, based almost entirely on
job titles, are likely to suffer from misclassifi-
cation. Although we could not adjust for
smoking in the analyses, we were able to
evaluate smoking data in a subgroup of
internally monitored workers. We found
that among those still employed in the
1980s, the proportion of current smokers
was substantially higher for unexposed than
for exposed workers. This disparity suggests
that negative confounding due to smoking
might be occurring in our cohort, potentially
obscuring the effect ofradiation exposure on
lung cancer mortality.
In summary, despite the small sample
size and relatively low lung doses recorded
for workers at RAI, this study has demon-
strated a dose-response association between
cumulative internal radiation dose and mor-
tality from hemato- and lymphopoietic can-
cers. In addition, we have seen evidence for a
dose-response association with upper aerodi-
gestive tract cancers that may have resulted
from the ingestion ofnonrespirable particles
that were cleared from the upper and lower
respiratory tract. Our latter finding is based
on a pooling of specific cancer types that
have not been examined as a group in previ-
ous radiation studies. Although we found
strong dose-response gradients for these two
types ofcancers, our estimates are imprecise
due to the small number of cases in each
group and should be confirmed by further
follow-up ofthe present cohort.
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